MASSBIOME REPORT OVERVIEW
END-TO-END MEDICAL
MICROBIOTA REPORT
Species-level resolution reporting powered by full-length 16S sequencing and an automated analysis pipeline. Actionable supplementary reports with physician guidance are also generated for clinical teams.
Not a diagnostic test.
Requires physician evaluation.
Two reports available.
REPORT SECTIONS
DIVERSITY (Alpha)
- Shannon Index
- Healthy threshold: ≥ 3.5
F/B Ratio
- Firmicutes / Bacteroidota
- Imbalance = dysbiosis
ENTEROTYPE
- Prevotella
- Bacteroides
- Ruminococcus
FUNCTIONAL GROUPS
- Acetate / Butyrate / Propionate
- LPS / Methane / Sulfate
PATHOGENS
- ≥ 1% threshold
- Ex: Klebsiella pneumoniae
BIOMARKERS
- Akkermansia muciniphila
- Faecalibacterium prausnitzii
GENERAL INFORMATION
THIS REPORT IS PERSONALIZED.
The content shown here is a sample presentation. To view detailed results generated from your own data, or to request a demo analysis, please proceed with the options below.
ALPHA DIVERSITY
In microbiome analyses, Alpha diversity refers to the species diversity among microorganisms within the gut.
Alpha Diversity
Shannon Index Result
High diversity and richness are essential for a healthy and resilient gut microbiota. The fundamental principle is that if one bacterial species is unable to perform its function, another can step in to compensate. When there are highly diverse and rich microorganisms in your gut, your immune system becomes stronger and more stable. Therefore, a high Alpha Diversity value is an indicator of a healthy microbiota.
Firmicutes/Bacteroidetes Ratio
Elevated F/B → indicates metabolic risks; low F/B → inflammatory bowel is an indicator of disease. Dietary and lifestyle modifications are recommended to restore balance.
YOUR RESULT
Current Bacterial Distribution
Healthy Reference
Ideal Bacterial Distribution
Firmicutes and Bacteroidetes are the two largest phyla of the human gut microbiome. The Firmicutes/Bacteroidetes ratio (F/B ratio) plays an important role in maintaining proper gut homeostasis is widely accepted. This ratio has been associated with various clinical disorders.
An increased or decreased F/B ratio is considered dysbiosis. An increase in the F/B ratio is associated with diseases such as obesity, type 2 diabetes, or non-alcoholic fatty liver disease, while a decrease in the F/B ratio is associated with inflammatory bowel disease. Therefore, proper maintenance of the balance between Bacteroidetes and Firmicutes in the gut is of great importance, particularly in the treatment of obesity and other metabolic issues.
ENTEROTYPE
Long-term dietary habits influence the dominant bacterial species in the human gut microbiome. The predominant bacteria in a person's microbiota are called enterotypes, and there are three different enterotypes:
PREVOTELLA
Carbohydrate Consumer
RUMINOCOCCUS
DOMINANT
Fiber and Resistant Starch Consumer
BACTEROIDES
Protein and Fat Consumer
- Bacteroides-dominant type is most commonly seen in individuals who consume large amounts of animal protein, lipids, and processed sugars.
- Ruminococcus-dominant type is most commonly seen in individuals with high carbohydrate intake. The Bacteroides-dominant type is most commonly associated with high consumption of animal protein, lipids, and processed sugars.
- Prevotella-dominant type is most commonly seen in individuals who consume high amounts of carbohydrates.
FUNCTIONAL GROUPS
Certain bacteria in the gut play a role in the breakdown or production of important compounds rol oynar. Bu bakterilere fonksiyonel gruplar denir.
The percentage of these bacteria provides clues about gut health. For example, bacteria that break down dietary fiber to produce short-chain fatty acids play an important role in gut health and are highly beneficial for strengthening the immune system. More detailed information is provided in the PDF output of the report. You can browse the sample report.
For more detailed information about functional groups, you can visit the relevant page by clicking the button below.
POTENTIALLY HARMFUL BACTERIA
Klebsiella pneumoniae %1.161 (above threshold). Clinical evaluation is recommended.
| BACTERIUM | BACTERIUM LEVEL | PERCENTILE RATIO (%) |
|---|---|---|
| Klebsiella pneumoniae | SPECIES | 1.161 |
Pathogenic bacteria are microorganisms capable of causing disease. Most bacteria are harmless and generally beneficial, but some species can cause infectious diseases and other health problems.
Despite the thousands of bacterial species in the gut flora, it is estimated that fewer than 100 pathogenic species can be found in the human intestine. Examples include Salmonella, Escherichia coli O157::H7, Staphylococcus aureus ve Streptococcus pyogenes are included. These pathogens can be transmitted to humans through food, water, air, contact, and animals. The normal gut microbiome contains various types of beneficial bacteria, and the presence of these beneficial bacteria can inhibit the growth of pathogenic bacteria. However, factors such as antibiotic use, immune system weakness, or digestive system diseases can affect the normal gut microbiome and lead to the proliferation of pathogenic bacteria.
It is important to protect the gut microbiome and prevent the growth of pathogenic bacteria. Pathogens detected at below 1% in the sample report have not been included in the table.
BIOMARKER BACTERIA
Certain bacteria naturally present in the gut can act as biomarkers and provide valuable insights into our health status.
| BACTERIUM | REFERENCE LEVEL | PERCENTILE RATIO (%) |
|---|---|---|
| Akkermansia muciniphila | >0.5 |
|
| Faecalibacterium prausnitzii | >1.0 |
|
| Bacteroides fragilis | <3.0 |
|
| Fusobacterium nucleatum | <0.98 |
|
| Helicobacter pylori | <0.03 |
|
| Clostridium difficile | <1.0 |
|
| Parabacteroides distasonis | >0.05 |
|
| Prevotella copri | <22.3 |
|
| Mediterraneibacter gnavus | <5.0 |
|
| Roseburia sp. | >0.2 |
|
| Collinsella aerofaciens | <5.0 |
|
A significant increase or decrease in the levels of biomarker bacteria may be an indicator of certain diseases. Therefore, the analysis of biomarker bacteria levels plays a crucial role in assessing gut health, predicting disease risks, and monitoring treatment processes.
Reference values have been specifically calculated for our analysis by comparing the relevant bacterial percentages of healthy and diseased individuals in our database with literature data.
If your biomarker bacteria level falls outside the reference range, it is recommended to consult a doctor.
You can visit the relevant page for detailed information about biomarker bacteria.
DISEASE-ASSOCIATED BACTERIA
IMPORTANT NOTICE
MassBiome is not a diagnostic test. If you have any concerns about the conditions mentioned, consulting a physician is strongly recommended.
SIMILAR MICROBIOME PROFILE
OBESITY
- Similarity Score72%
TYPE 2 DIABETES
- Similarity Score85%
DIFFERENT MICROBIOME PROFILE
ALZHEIMER
- Similarity Score12%
IRRITABLE BOWEL SYNDROME (IBS)
- Similarity Score25%
MENTAL HEALTH
How Does It Work? Your microbial composition is compared against profiles of individuals associated with these conditions. A high similarity indicates that your microbiome resembles the profile seen in these conditions; it is not a definitive diagnosis.
ASSESSED CONDITIONS AND RISK PROFILES
PROBIOTICS
| BACTERIUM | BACTERIUM STATUS | ACTIVE PROBIOTICS |
|---|---|---|
| Enterococcus facium |
|
|
| Bifidobacterium longum |
|
VITAMIN-RELATED BACTERIA
NUTRITION RECOMMENDATIONS
frequently asked questions (FAQ)
How are data security and KVKK (Turkish data protection) processes managed?
MassBiome does not collect data of any kind, nor does it share data with any stakeholders outside your institution. All your data is stored exclusively on your own high-capacity on-premises MassBiome-equipped computers provided by Massive Bioinformatics — under your full control — accessible only to you and under your stewardship.
Which Oxford Nanopore devices is MassBiome compatible with?
MassBiome is fully compatible with .pod5 and .fastq data from MinION (Mk1B/Mk1C/Mk1D), GridION, and PromethION devices.
What is the Turnaround Time?
After the sample arrives at the laboratory, the final report can be generated within an average of 3–5 business days, including sequencing and bioinformatic analysis.
Is on-premises (On-Premise) installation possible?
Yes. MassBiome was designed with precisely this vision in mind — to enable institutions that require data sovereignty to generate value from their own data within their own infrastructure.
Can I request a demonstration before installing the system?
Absolutely. At Massive Bioinformatics, we understand how much high investment costs strain institutions. For this reason, we are confident in the return on investment we offer and can support your institution with various types of demonstrations.